BioMedNewsBreaks – iHealthScreen to Host Upcoming Webinar, Report on Fundraising Efforts

iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, has scheduled an exclusive Q&A webinar. CEO Alauddin Bhuiyan will host the event, which is slated for July 11, 2023, at 9 a.m. PDT. During the webinar, Bhuiyan will provide an overview of the company, including how iHealthScreen is disrupting the billion-dollar health screening market; he will also discuss the unique benefits of iHealthScreen’s investment opportunity, which capitalizes on the company’s proprietary AI-driven, health-screening software. According to the announcement, iHealthScreen is one of the first companies in the world to receive CE certification and Australian and UAE health approvals for the screening of age-related macular degeneration (“AMD”), diabetic retinopathy (“DR”) and glaucoma.

To attend the webinar, visit https://ibn.fm/4ZkRd

To view the full press release, visit https://ibn.fm/3O0Ad

About iHealthScreen

iHealthScreen’s integrated, retinal imaging-based system makes it one of the first companies in the world to receive CE certification, Australian and UAE health approvals for AMD, DR and glaucoma screening. The company is gaining international traction with contracts in the United States, European Union, Bangladesh and UAE; the company has also been collaborating with Global Victoria in Australia. For more information, please visit www.StartEngine.com/offering/iHealthScreen.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

2 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

3 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

4 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

5 days ago